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ABSTRACT 
Background: Although recorded cancer mortality should include both deaths from cancer and 
deaths from cancer treatment, there is some evidence suggesting that the measure may be 
incomplete.  To investigate the completeness of recorded prostate cancer mortality, we compared 
other-cause (non-prostate cancer) mortality in men found and not found to have prostate cancer 
following a needle biopsy. 
 
Methods: We linked Medicare claims data to Surveillance, Epidemiology, and End Results 
(SEER) data to analyze survival in the population of men aged 65 years and older enrolled in 
Medicare Part B who resided in a SEER area and who received a needle biopsy of the prostate in 
1993 through 2001.  We compared other-cause mortality in men found to have prostate cancer 
(n= 53,462) to that in men not found to have prostate cancer (n = 103,659). 
 
Results:  The age-race adjusted other-cause mortality rate was 471 per 10,000 person-years in 
men found to have prostate cancer vs. 468 per 10,000 in men not found to have prostate cancer 
(RR = 1.01; 95% CI: 0.98 - 1.03).  The effect was modified, however, by age.  The RR declined 
in a stepwise fashion from 1.08 (95% CI 1.03 – 1.14) in men age 65-69 to 0.89 (95% CI 0.83 – 
0.95) in men age 85 and older.  If the excess (or deficit) in other-cause mortality were added to 
the recorded prostate cancer mortality, prostate cancer mortality would rise as much as 23% in 
the youngest age group (from 90 to 111 per 10,000) and would fall as much as 30% in the oldest 
age group (from 551 to 388 per 10,000). 
 
Conclusion: Although recorded prostate cancer mortality appears to be an accurate measure 
overall, it systematically underestimates the mortality associated with prostate cancer diagnosis 
and treatment in younger men and overestimates it in the very old.  We surmise that in younger 
men treatment-related deaths are incompletely captured in recorded prostate cancer mortality, 
while in older men the diagnosis “sticks” – once diagnosed, they are more likely to be said to 
have died from the disease. 
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The best indicator of progress against cancer is a decline in population-based cancer mortality 
rates.1  One strategy to achieve such progress is early diagnosis.  But because early diagnosis 
almost always means more patients are diagnosed and treated for cancer than would be 
otherwise, it is possible that while mortality from advanced cancer falls – treatment-related 
mortality rises.  Thus to ensure that progress is genuine, cancer mortality should include not only 
deaths from cancer, but also deaths from cancer treatment. 
 
There are reasons to worry that treatment-related mortality may not be reliably included in the 
measurement of cancer mortality.  Although the World Health Organization's definition of the 
underlying cause of death clearly encompasses treatment-related mortality ("the disease or injury 
which initiated the train of morbid events leading directly to death")2, the instructions of US 
National Center for Heath Statistics on coding the underlying cause of death contain conflicting 
guidance on whether treatment-related mortality should be attributed to cancer or to an 
"accident" (i.e. a medical misadventure)3.  Empirical evidence bears out that some confusion 
exists.  One of us (HGW) reported that 41% of deaths within a month following cancer-directed 
surgery were not attributed to the cancer for which the surgery was performed.4  And Brown et 
al.  reported that other-cause (non-cancer) mortality was considerably higher in cancer patients 
than in the general population - particularly in the year immediately following the diagnosis.5 
 
Enumerating treatment-related mortality may be particularly important in prostate cancer given 
the increasing use of androgen deprivation therapy, not only for metastatic disease, but also for 
earlier stage disease.  Roughly a quarter-million Medicare eligible men now receive this therapy 
– almost 3% of all men in Medicare6.  A recent meta-analysis of  (conducted as part of an 
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American Society of Clinical Oncology practice guideline update) suggested that androgen 
deprivation therapy may be associated with a 15% increase in other-cause mortality7, perhaps 
reflecting an increased risk of cardiovascular disease8. These deaths would be unlikely to be 
attributed to prostate cancer in vital statistics. 
 
In this paper, we refine Brown's approach to consider the validity of recorded prostate cancer 
mortality.  Here there is little doubt about the effect of early diagnosis on the number of men 
treated for the disease - hundreds of thousands of additional men have been treated for prostate 
cancer following the introduction of the PSA.  Thus even if the individuals mortality risk from 
treatment were small, recorded prostate cancer mortality could be substantially undercounted 
were treatment-related mortality not included.  We hypothesized that among a cohort of men 
undergoing prostate biopsy this undercount would appear as elevated other-cause mortality in 
those found to have prostate cancer relative to those not found to have prostate cancer. 
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METHODS 
Overview 
To make an inference about the completeness of recorded prostate cancer mortality, we 
compared other-cause mortality in men found and not found to have prostate cancer following a 
needle biopsy.  We postulated that by starting with a cohort of men undergoing biopsy we could 
construct groups that were otherwise comparable - with the exception of the known prostate 
cancer risk factors of age and race.  In other words, although some men would be found to have 
prostate cancer and some would not, the two groups would be otherwise similar because they 
share the same characteristics that led to biopsy.  Thus if age-race adjusted other-cause mortality 
was higher in the group diagnosed with prostate cancer, we would infer that measured prostate 
cancer mortality was incomplete. 
 
Mechanically, the analysis required two data sources.  We used the Medicare National Claims 
History System (Source: Health Care Financing Agency; Baltimore, MD) both to identify the 
cohort of men undergoing biopsy and to determine the fact of death.  We used the Surveillance 
Epidemiology and End Results (SEER) data to determine which men were diagnosed with 
prostate cancer and to determine their cause of death. 
 
Although a linked Medicare-SEER dataset already exists, it only includes data on beneficiaries 
with cancer and a 5% sample of controls.  Because our analysis required survival data for an 
entire population of men undergoing prostate biopsy (both those who did and did not receive a 
prostate cancer diagnosis), we needed to create a new Medicare-SEER linkage.  This study was 
approved by the Dartmouth institutional review board. 
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Study Population  
We identified all men with a Medicare Part B claim for a needle biopsy of the prostate (identified 
using the Current Procedure Terminology (CPT) code 55700) who resided in a SEER area during 
the period 1993-2001.  We first used the Medicare denominator file to restrict the analysis to 
men who resided in one of the SEER 11 areas (5 states: Connecticut, Hawaii, Iowa, New 
Mexico, and Utah; 6 metropolitan areas Atlanta, Detroit, Los Angeles, San Francisco, San Jose, 
and Seattle) both in the year of the biopsy and the subsequent year.  In other words, we created a 
dataset of prostate biopsies performed in men who we could ensure resided in a SEER area at the 
time of the biopsy – a restriction necessary to capture the diagnosis of prostate cancer in SEER.  
 
We then excluded three groups using demographic exclusion criteria.  First, we excluded 
biopsies in men who were not age 65 and older at the start of each calendar year (both because 
individuals who become eligible for Medicare for reasons other than age represent a very unique 
group and because those who become eligible mid-year will not have complete data).   Second, 
we excluded those men not entitled to Part B for the entire year (as diagnostic services provided 
to them are not reported in the claims).  Third, we excluded those in men enrolled in risk-
contract managed care plans (for the same reason).  
 
We then excluded two more groups of biopsies using clinical exclusion criteria.  First, we 
excluded biopsies in men with a concomitant TURP (transurethral resection of the prostate), 
defined as one within a five month window surrounding the prostate biopsy, as it would not be 
clear whether to attribute a prostate cancer diagnosis to the TURP or the biopsy.  Second, we 
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excluded biopsies in men with a prior prostate cancer diagnosis.  Following these exclusions our 
study cohort consisted of 157,121 men undergoing needle biopsy of the prostate. 
 
Exposure: Prostate Cancer Diagnosis 
To determine which of these men were diagnosed with prostate cancer, we linked the Medicare 
beneficiary ID to the SEER data.  A member of our cohort was determined to develop prostate 
cancer if he appeared in the SEER data as an incident cancer case with a primary site 
International Classification of Disease – Oncology (ICD-O) code of C619. 
 
As in our prior work9, we considered a prostate cancer diagnosis within 1 month prior to and 3 
months after the biopsy date as being attributable to the biopsy (SEER only codes the month of 
diagnosis - given a biopsy date of 12/4/93, a prostate cancer diagnosis accessed in 11/93, 12/93 
or 1/94, 2/94, 3/94 would be attributed to the biopsy).  Our use of this 5 month window reflected 
the empirical observations that an excess number of prostate cancer diagnoses appeared in this 
period: some in the month prior to biopsy (likely representing SEER linking the date of diagnosis 
to the PSA test prompting the biopsy) and some in the months following the biopsy (representing 
a time lag).  Using our SEER-Medicare linkage we determined that 53,462 men were found to 
have prostate cancer following the needle biopsy and 103,659 men were not found to have 
prostate cancer. 
 
Outcome: Other Cause Mortality 
 Our primary outcome is other-cause mortality (expressed as deaths per 10,000 person 
years).  For all members in our cohort, the fact of death and its date was obtained from Medicare 
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denominator file.  For the 53,462 men found to have prostate cancer (who appear in the SEER 
data), the underlying cause of death was obtained in SEER data.  Other-cause mortality was 
determined by removing those deaths attributed to prostate cancer (those that encompass 
measured prostate cancer mortality) from all deaths combined.  Because the 103,659 men not 
found to have prostate cancer either never receive the diagnosis of prostate cancer or are 
censored when they do (as detailed below), other-cause mortality simply reflects all deaths 
combined.  
 
Survival Analysis  
Given that members of our cohort could enter any time over the 9-year period (1993-2001), the 
length of follow-up was variable.  To deal with the problem of variable follow-up we used 
survival analysis.   
 
For all members of the cohort, survival time is calculated from the date of the index biopsy.  The 
failure event is a death from something other than prostate cancer (date = date of death).  The 
most frequent censoring event was simply the study closure date – chosen to provide a minimum 
of 2 years of follow-up (date = 12/31/03).  Members were also censored at the time relevant data 
were no longer available: moving out of a SEER area and leaving Medicare Part B (either 
because of not purchasing it or because of entering a risk-contract HMO). 
 
Two censoring events were distinct among the two groups.  Men found to have prostate cancer 
were censored if they died from prostate cancer.   In other words, on the date of prostate cancer 
death they are no longer "at risk" for the failure event - death from something other than prostate 
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cancer.  Men not found to have prostate cancer were censored if they were diagnosed with 
prostate cancer.  At this point, they are no longer a member of their original exposure group.  
Figure 1 shows the study overview and the number experiencing the various censoring events. 
 
Figure 1: Study Overview 
 
 
 
 
 
Covariates 
 
The age and race of the members of our cohort was determined from the Medicare denominator 
file.  Age is measured as the difference between the beneficiary’s birth date and the date of the 
index biopsy.   
 
To establish the baseline comparability between the two groups, we also measured health care 
utilization in the year prior to biopsy.  The fact of hospital admission, the DRG weight (used to 
calculate hospital charge) and the length of stay were obtained from the Medicare MEDPAR 
(Part A) data.  Inpatient and outpatient physician visits and outpatients charges were obtained 
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from Medicare Part B.  The two comorbidity measures (the Charlson comorbidity score10 and 
Iezzoni's number of comorbidities11) were calculated based on ICD-9 diagnosis codes from both 
MEDPAR and Part B data.  A comorbidity is identified if one condition is shown at least twice 
(and seven days apart) in the baseline year. 
 
Adjustment methods 
We compared their health care utilization in the year prior to biopsy after adjusting for expected 
age-race differences (men with prostate cancer would be older and more likely to be black).  We 
used men found to have prostate cancer as the standard (referent) population and determined 
what utilization would have been expected for men not found to have prostate cancer if their age-
race structure were matched to the first group.  This was done with model-based direct 
adjustment.  We used multiple linear regression (and logistic regression for the dichotomous 
variable of hospitalization yes/no) in which the dependent variable was the utilization variable 
and the independent variables were age, race and group (in which the referent category was men 
found to have prostate cancer).  The coefficient on group was then added (or multiplied in the 
case of the logistic regression) to the crude data for men found to have prostate cancer to produce 
the adjusted data for men not found to have prostate cancer.  This process is analogous to 
propensity matching. 
 
Our primary outcome metric is the relative rate of other-cause mortality (men found vs. men not 
found to have prostate cancer).  We first present the crude relative risk and then move through a 
series of stepwise adjustments for potential confounders.   For each step men found to have 
prostate cancer serve as the standard population (i.e. - the crude value for this group remains 
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stable throughout the adjusted analyses).  This was done because we wanted to calculate the 
effect of transferring an excess (or deficit) in other-cause mortality to prostate cancer mortality –
which, because it only occurs in the group found to have prostate cancer, cannot be adjusted. 
 
We first adjust the relative rate simply for the expected confounders of age and race.  We used 
two methods: a Cox Proportional Hazards model (in which age is a continuous variable) and 
indirect age-race adjustment (using 4 age categories and 3 race categories - producing a total of 
12 age-race cells).  Because these methods yielded essentially identical results, we proceeded to 
use the Cox model to sequentially add covariates reflecting health care utilization in the year 
prior to biopsy.   
 
We also used two approaches to produce  95% confidence intervals around the relative rate: 
those obtained from the Cox model and by using the bootstrap method.  Because these methods 
also yielded essentially identical results, we report those from the Cox model.  Analyses were 
performed using either SAS 9.1 (SAS Institute Inc, Cary, NC) or STATA 10 (Stata Corp, 
College Station, TX). 
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RESULTS 
Table 1 shows the age-race structure of our study population.  As expected, the average age of 
men found to have prostate cancer was about a year older than those not found to have prostate 
cancer (73.8 vs. 72.7 years).  Also as expected, men found to have prostate cancer were slightly 
more likely to be black (8.6% vs. 7.1%).   
 
 
Table 1. Demographics of the study population* 
Characteristic 
Men found 
 to have prostate cancer 
(N = 53,462) 
Men not found 
 to have prostate cancer 
(N = 103,659) 
 Age (mean) 73.8 72.7 
 Age Group (%)   
 65-69 years 27.2 33.2 
 70-74 years 32.3 33.7 
 75-79 years 23.8 21.3 
 80-84 years 11.5 8.5 
 >85 years 5.2 3.2 
Race (%)   
 White  82.7 81.1 
 Black 8.6 7.1 
 Others 8.7 11.8 
 
* for all comparisons p < 0.001  
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Table 2 shows that after age-race adjustment, however, health care utilization in the year prior to 
biopsy was nearly identical in the two groups.  Of the 8 variables measured, 2 suggested that 
illness burden was trivially higher in men found to have prostate cancer while 6 suggested the 
opposite (sign test p = .29). 
 
 
Table 2. Comparison of health care utilization in the year prior to biopsy in men found and not found to have 
prostate cancer.*  All data are age and race adjusted. 
Characteristic‡ 
Men found 
 to have prostate cancer 
[N = 53,462] 
(a) 
Men not found 
 to have prostate cancer 
[N = 103,659] 
(b) 
 
Direction 
of effect 
(a –b) 
Inpatient Care    
 % admitted to hospital 13.7 14.5 – 
 Mean hospital charge using 
DRG weight ($)* $4,868 $4,737 + 
 Mean LOS per admission 
(days) 4.09 4.11 – 
 Mean physician visits per 
admission 3.00 3.07 – 
Outpatient Care    
 Mean outpatient visits 15.2 16.5 – 
 Mean outpatient charges ($)† $1,911 $2,121 – 
 Charlson Comorbidity Score  0.665 0.632 + 
 # of comorbidities (Iezzoni) 0.721 0.735 – 
 
* for all comparisons p < 0.001  
† based on 2000 prices. 
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Table 3 shows the crude other-cause mortality rates in the two groups and the effect of various 
adjustments.  The age-race adjusted other-cause mortality rate was 471 per 10,000 person-years 
in men found to have prostate cancer vs. 468 per 10,000 in men not found to have prostate cancer 
(RR = 1.01; 95% CI: 0.98 - 1.03).  Subsequent adjustments using the various measures of prior 
utilization had minimal effect.  
 
  
Table 3. Other-cause mortality in men found and not found to have prostate cancer.  
 
OTHER-CAUSE MORTALITY 
(Rate per 10,000 person-years) 
 
Control Variables 
Men found 
 to have prostate cancer 
(N = 53,462) 
Men not found 
 to have prostate cancer 
(N = 103,659) 
 
Relative Rate 
(95% CI) 
Crude 471 429 
1.098 
(1.07 – 1.12) 
Age, Race 471 468 
1.006 
(.98 – 1.03) 
Age, Race, Inpatient 
utilization (Hospitalization, 
DRG weight, LOS, 
physician visits) 
471 461 
1.021 
(1.00 – 1.04) 
Age, Race, Inpatient 
utilization, Outpatient 
utilization (visits, charges) 
471 458 
1.029 
(1.01 – 1.05) 
Age, Race, Inpatient 
utilization, Outpatient 
utilization, Comorbidity 
scores (Charlson, Iezonni) 
471 461 
1.021 
(1.00 – 1.04) 
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Figure 2 shows that the other-cause survival curves for men found and not found to have 
prostate cancer are superimposed on one another – suggesting that our original hypothesis that 
other-cause mortality would be higher in men found to have prostate cancer was incorrect.  
 
Figure 2: Survival Analysis – the age-race adjusted risk of not dying from other causes in men found and not 
found to have prostate cancer. 
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As shown in Figure 3, however, it became apparent that this effect (or lack thereof) was 
modified by age.  In the youngest age stratum (age 65-69) there was an excess in other-cause 
mortality in men found to have prostate cancer, while in the oldest age stratum (age 85+) there 
was a deficit.  
 
Figure 3: Restricted Survival Analyses – the age-race adjusted risk of not dying from other causes in men 
found and not found to have prostate cancer for the two extremes of age: age 65-69 and age 85+. 
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Figure 4 shows the results of restricted analyses for each of five age strata.  The relative rate of 
other cause mortality in men found vs. men not found to have prostate cancer declined in a 
stepwise fashion from 1.08 (95% CI 1.03 – 1.14) in men age 65-69 to 1.05 (95% CI 1.01 – 1.10) 
in men age 70-74 to 1.03 (95% CI 0.99 – 1.08) in men age 75-79 to 0.96 (95% CI 0.91 – 1.01) in 
men age 80-84 to 0.89 (95% CI 0.83 – 0.95) in men age 85 and older.  The figure also shows that 
the proportion of men receiving definitive therapy for prostate cancer (surgery or radiation) fell 
dramatically with increasing age.  
 
Figure 4: Restricted Analyses – the age-race adjusted relative rate of other-cause mortality in men found vs. 
those not found to have prostate cancer in each of five age strata. 
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If the excess (or deficit) in other-cause mortality observed above were added to recorded prostate 
cancer mortality (which was 153 per 10,000 among all men found to have prostate cancer), 
prostate cancer mortality would rise 23% in the youngest age group (from 90 to 111 per 10,000) 
and would fall 30% in the oldest age group (from 551 to 388 per 10,000).  The potential change 
in recorded prostate cancer mortality for each of the 5 age strata is shown in Figure 5. 
 
 
Figure 5: Percentage change in recorded prostate cancer mortality in five age strata if surplus (or deficit) in 
other-cause mortality were attributed to prostate cancer. 
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DISCUSSION 
We investigated other-cause mortality in a cohort of over 150,000 male Medicare beneficiaries 
undergoing needle biopsy of the prostate during the period 1993-2001.  Although we 
hypothesized that other-cause mortality would be higher in those found to have prostate cancer 
than in those who were not found to have the disease, we found no evidence to support this in 
our overall analysis. 
 
We were surprised, however, that this null finding obscured a substantial effect modification by 
age.  In younger men (age 65 to 69 and 70 to 74) other-cause mortality was significantly higher 
in men found to have prostate cancer.  Over three-quarters of these men received definitive 
therapy for their disease (surgery or radiation).  We suspect that the excess other-cause mortality 
reflects the "slippery diagnosis" bias12 in which treatment-related deaths are attributed to other 
causes.  We should acknowledge that, at the individual level, the cause of death may be quite 
ambiguous: a man dying from a heart attack in the week following a radical prostatectomy or a 
man dying from a pelvic abscess two years after radiation therapy to the prostate.  But, at the 
population level, the bias becomes evident.  Although the excess in other-cause mortality among 
younger men was relatively small (8% for men age 65-69 and 5% for men age 70-74), the 
potential impact on recorded prostate cancer mortality would be relatively large (an increase of 
24 and 18% respectively).  
 
In older men the effect was reversed.  Among men age 85 and older other-cause mortality was 
significantly lower in men found to have prostate cancer.  The overwhelming majority of these 
men did not receive definitive therapy for their disease.  This deficit in other-cause mortality may 
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represent "sticky diagnosis" bias9 in which older men - once diagnosed - are more likely to be 
said to die of the disease – particularly since most are not treated.  Others have suggested that the 
decision to treat may influence decisions about cause of death: that there may be a reluctance to 
attribute deaths to prostate cancer in men receiving definitive treatment and, conversely, a 
willingness to attribute deaths to prostate cancer (rather than something else) in men not 
receiving definitive treatment13.   
 
As with any observational study, the central concern about our findings must be confounding.  
Since men cannot be randomized to receive or not receive the diagnosis of cancer, inferences 
about the completeness of cancer mortality will necessarily depend on observational data to 
produce information on the mortality expected in the absence of cancer.  Our approach was to 
examine a cohort of men who were all undergoing the diagnostic procedure used to evaluate the 
presence of disease and then compare other-cause mortality in those found and not found to have 
the disease.  We believe this approach avoids the fundamental biases associated with a 
comparison of men diagnosed with prostate cancer to those in the general population (either 
reduced mortality due to a healthy screenee effect or increased mortality due those co-morbid 
conditions that may produce symptoms that lead to cancer testing).  In fact, after adjusting for the 
expected differences found in age and race, we were able to demonstrate that the illness burden 
(as measured by health care utilization in the year prior to biopsy) was virtually identical.  This 
finding held true not only for the overall analysis, but in each of the five age groups in the 
restricted analyses. 
 
  RECORDED PROSTATE CANCER MORTALITY - 21 
 Our analysis has other limitations. While we have data regarding the cause of death in 
men diagnosed with prostate cancer (because cause of death is recorded in SEER), we do not 
have cause of death data in the men not diagnosed (Medicare data contains the fact of death, not 
the cause).  Thus we cannot further enumerate the observed discrepancies in other-cause deaths 
within the various age groups.  We also do not have data on number of needle cores obtained 
during the prostate biopsy – a number that undoubtedly increased over the years analyzed here.  
We were able to confirm, however, that our observation of effect modification by age was not 
sensitive to the year of diagnosis - a reasonable proxy for the increasing number of cores. 
Implications 
 It is important to emphasize two inferences that should not be made based on our data.  
First, our data should not be taken as evidence that the observed decline in prostate cancer 
mortality in the United States is spurious (about 4% per year since 199414).  Declining mortality 
has been occurring within each age stratum and we have no evidence of a sufficiently large 
change in patterns of treatment or death attribution over time to explain these trends as being 
anything other than real. 
 
 Second, our data also have no bearing on the debate about whether PSA screening 
reduces prostate cancer mortality.  Our findings are equally consistent with the possibility that 
PSA screening reduces prostate cancer mortality, increases it, or has no effect at all. 
 
 Instead, our findings highlight the ambiguities in determining the underlying cause of 
death.  They reinforce the need for expansive definitions of treatment-related death by death 
review committees that serve those randomized trials that depend on cancer-specific mortality as 
a primary outcome.  And that, because uncertainties are bound to persist, investigators and 
editors should strive to obtain a less ambiguous outcome – all-cause mortality. 
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